A kinetic model for simultaneous fit of clozapine and norclozapine concentrations in chronic schizophrenic patients during long-term treatment

Clinical Drug Investigation

Volumn 16, Issue 1, 1998, Pages 35-43

  Guitton, Claire ^a   Kinowski, Jean Marie ^a   Gomeni, Roberta ^b,c   Bressolle, Françoise ^b  

^a DEPARTMENT OF NEUROLOGY   (France)

^b UNIV MONTPELLIER   (France)

^c Zeneca Laboratoires   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NORCLOZAPINE;

ADULT; ARTICLE; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONSTIPATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FATIGUE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERSALIVATION; MALE; METHODOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0031903114     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199816010-00005     Document Type: Article

References (54)

1. Jann MW. Evaluations of new drugs. Clozapine. Pharmacotherapy 1991; 1: 179-95
2. Farde L. Wiesel FA, Nordstrom AL, et al. D-I and D-2 dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl) 1989; 99 Suppl.: S28-31
3. Waddington JL. Neuroleptic/dopamine receptors. Eur J Pharmacol 1990; 183: 106
4. Wander TJ. Nelson A, Okazaki H, et al. Antagonism by neuroleptics of serotonine 5-HT-1A and 5-HT-2 receptors of normal human brain in vitro. Eur J Pharmacol 1987; 143: 279-82
5. Canton H. Verriele L, Colpert FC. Binding of typical and atypical antipsychotics to 5-HT-1C and 5-HT-2 sites: clozapine potently interacts with 5-HT-1C sites. Eur J Pharmacol 1990; 191 : 93-6
6. Kuoppamaki M, Syvalahiti E. Hietala J. Clozapine and Ndesmethylclozapine are potent 5-HTlc receptor antagonists. Eur J Pharmacol 1993; 245: 179-82
7. Baldessarini DE, Frankenburg FR. Clozapine a novel antipsychotic agent. N Engl J Med 1991; 324: 746-54
8. Kane J. Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatr 1988; 45: 789-96
9. Safferman A, Lieberman J, Kane J, et al. Update on clinical efficacy and side-effects of clozapine. Schizophr Bull 1991; 17: 247-62
10. Lieberman JA, Kane JM. Johns CA. Clozapine guidelines for clinical management, J Clin Psychiatry 1989; 50: 329-38
11. Krupp P, Barnes P, Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology (Berl) 1989; 99 Suppl.: S118-21
12. Gerlack J, Peacock L. Motor and mental side-effects of clozapinc. J Clin Psychiatry 1994; 55 Suppl. B: 107-9
13. Dumortier G, Cohen de Melo P, Célis C, et al. Interactions pharmacocinétiques de la clozapine. L' Information Psychiatrique 1996 Oct; 72: 832-6
14. Jerling M, Lindstrom L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16: 368-74
15. Hiemke C, Weigmann H, Hartter S, et al. Elevated levels of clozapine in serum after addition of fluvoxamine [letter]. J Clin Psychopharmacol 1994; 14 (4): 279-81
16. Bertilsson L, Carrillo JA, Dahl ML. et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 38: 471-3
17. Eiermann B, Engel G, Johansson l, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997; 44 (5): 439-46
18. Choc MG, Lehr RG, Hsuan F, et al. Multiple-dose pharmacokinetics of clozapine in patients. Pharm Res 1987; 4 (5): 402-5
19. Choc MG, Hsuan F, Honigfeld G, et al. Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res 1990; 7: 347-51
20. Cheng YF, Lundberg T, Bondesson U, et al. Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur J Clin Pharmacol 1988; 34: 445-9
21. Gu NF. Pharmacokinetic study of clozapine. Chung-Hua Shen Ching Ching Shen Ko Tsa Chih 1988; 21: 259-62
22. Ackenheil M. Clozapine-pharmacokinetic investigations and biochemical effects in man. Psychopharmacology (Berl) 1989; 99 Suppl.: S32-S37
23. Verghese C. Kessel JB. Simpson GM. Pharmacokinetics of neuroleptics. Psycopharmacol Bull 1991; 27 (4): 551-63
24. Dollo G, Bun H, Bonnefont-Cornet M. Dosage de la clozapine plasmatique par Chromatographie en phase liquide et applications au suivi thérapeutique. J Pharm Clin 1994: 13: 17-22
25. Preterre PH. Clozapinemie et ajustement thérapeutique. L'Encéphale 1995; Suppl. III: 53-7
26. Jerling M, Merle Y. Mentré F. et al. Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. Br J Clin Pharmacol 1997; 44 (5): 447-53
27. Lin SK, Chang WH, Chung MC, et al. Disposition of clozapine and desmethylelozapine in schizophrenic patients. J Clin Pharmacol 1994; 34: 318-24
28. Centorrino F, Baldessarini RJ, Kando JC, et al. Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol 1994; 14 (2): 119-25
29. Perry PJ, Miller DD, Arndt SV. et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment refractory schizophrenic patients. Am J Psychiatry 1991 Feb; 148 (2): 231-5
30. Bondesson U, Lindström LH, Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chomatography-mass spectrometry with single ion detection. Psychopharmacology (Berl) 1988; 95 (4): 472-5
31. Ackenheil M, Bräu H. Burkhart A, et al. Antipsychotic efficacy in relation to plasma concentrations of clozapine. Arzneimittelforschung 1976; 26: 1156-8
32. Bräu H, Burkhart A, Pacha W, et al. Relationship between effects and plasma concentrations of clozapine. Arzneimittelforschung 1978; 29: 1300
33. Miller DD, Fleming F, Holman TL, et al. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 1994 Sep; 55 Suppl. B: 117-21
34. Lieberman JA, Kane JM, Safferman AZ, et al. Predictors of response to clozapine. J Clin Psychiatry 1994 Sep; 55 Suppl. B: 126-8
35. Pickar D, Owen RR, Litman RE, et al. Predictors of clozapine response in schizophrenia. J Clin Psychiatry 1994 Sep: 55 Suppl. B: 129-32
36. Potkin SG, Bera R, Gulasekraram B, el al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994 Sep: 55 Suppl. B: 133-6
37. Chong SA, Tan CH, Khoo YM, et al. Clinical evaluation and plasma clozapine concentrations in Chinese patients with schizophrenia. Ther Drug Monit 1997; 19: 219-23
38. Spitzer RL, Williams JB, Gibbon M, et al. Structural clinical interview for DSM-III-R: patient edition (SCID-P. Version 10). Washington. DC: American Psychiatric Press. 1990
39. Guy W, Clinical Global Impressions scale. ECDEU assessment manual for psychopharmacology. US Dept Health Education and Welfare publication (ADM) 76-338 Rockville. Maryland: National Institute of Mental Health: 1976: 218-22
40. Guitton C, Kinowski JM, Aznar R, et al. Determination of clozapine and its major metabolites in human plasma and red blood cells by high-performance liquid chromatography with UV absorbance detection. J Chromatogr 1997; 690: 211-22
41. Kinowski JM, de la Coussaye JE, Bressolle F, et al. Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration. J Antimicrob Agents Chemother 1993 Mar; 37 (3): 464-73
42. Galtier M. Bressolle F, de la Coussaye JE, et al. Multiple-dose pharmacokinetics of pefloxacin in patients with hepatocellular insufficiency. Clin Pharmacokinet 1993; 25 (5): 415-23
43. Costa P, Bressolle F, Jarroux E, et al. Multiple-dose pharmacokinetics of moxisylyte after oral administration to healthy volunteers. J Pharm Sci 1993 Sep; 82 (9): 968-71
44. Bressolle F, Gallier M, Kinowski JM, et al. Multiple-dose pharmacokinetics of ceftibuten after oral administration to healthy volunteers. J Pharm Sci 1994 Sep; 83 (9): 1236-40
45. Pk-fit computer program, version 1.1. 1997. RDPP, Montpellier. France
46. Draper NR, Smith H. Applied regression analysis. New York: John Wiley & Sons. 1966
47. Haring C, Meise U, Humpel C. et al. Dose-related plasma concentrations of clozapine: influence of smoking behavior, sex. and age. Psychopharmacology (Berl) 1989; 99 Suppl.: S38-S40
48. Fisher V, Vogels B, Maurer G, et al. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P-450 2D6. J Pharmacol Exp Ther 1992; 260: 1355-60
49. Dahl ML, Llerena A, Bondesson U. et al. Disposition of clozapine in man: lack of association with debresoquine and Smephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol 1994; 37: 71-4
50. Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry 1997 Aug; 171; 109-12
51. Jann MW, Grimsley SR, Gray EC, et al. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993; 24 (2): 161-76
52. Miller DD. Effect of phenytoin on plasma clozapine concentration in two patients. J Clin Psychiatry 1991; 52: 23-5
53. Centorrino F, Baldessarini RJ, Kando JC, et al. Serum concentration of clozapine and major metabolites. Effects of cotreatment with valproate or fluoxetine. Am J Psychiatry 1994; 151: 123-5
54. Scymanski S, Lieberman JL, Picou D, et al. A case report of cimetidine induced clozapine toxicity. J Clin Psychiatry 1991; 52: 21-2